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disease of bone. In the present study, we analyzed the 
SQSTM1 coding sequence for mutations in an extended 
cohort of 1,808 patients with frontotemporal lobar 
degeneration (FTlD), ascertained within the european 
early-Onset Dementia consortium. As control dataset, 
we sequenced 1,625 european control individuals and 
analyzed whole-exome sequence data of 2,274 ger-
man individuals (total n = 3,899). Association of rare 
SQSTM1 mutations was calculated in a meta-analysis of 
4,332 FTlD and 10,240 control alleles. We identified 
25 coding variants in FTlD patients of which 10 have 
Abstract Mutations in the gene coding for Seques-
tosome 1 (SQSTM1) have been genetically associated 
with amyotrophic lateral sclerosis (AlS) and Paget 
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not been described. Fifteen mutations were absent in the 
control individuals (carrier frequency <0.00026) whilst 
the others were rare in both patients and control indi-
viduals. When pooling all variants with a minor allele 
frequency <0.01, an overall frequency of 3.2 % was 
calculated in patients. rare variant association analy-
sis between patients and controls showed no difference 
over the whole protein, but suggested that rare muta-
tions clustering in the UBA domain of SQSTM1 may 
influence disease susceptibility by doubling the risk 
for FTlD (rr = 2.18 [95 % CI 1.24–3.85]; corrected 
p value = 0.042). Detailed histopathology demonstrated 
that mutations in SQSTM1 associate with widespread 
neuronal and glial phospho-TDP-43 pathology. With 
this study, we provide further evidence for a putative 
role of rare mutations in SQSTM1 in the genetic eti-
ology of FTlD and showed that, comparable to other 
FTlD/AlS genes, SQSTM1 mutations are associated 
with TDP-43 pathology.
Keywords Sequestosome 1 · SQSTM1 · p62 · FTlD · 
AlS · rare variants
Introduction
Frontotemporal lobar degeneration (FTlD) represents a 
heterogeneous group of progressive neurodegenerative 
dementias, caused by local atrophy of frontal and/or tem-
poral lobes. It is one of the most common forms of early-
onset dementia (eOD), with the majority of FTlD patients 
developing disease between 45 and 65 years. About 15 % 
of FTlD patients present with a motor neuron disease 
(MND) syndrome, most commonly amyotrophic lateral 
sclerosis (AlS). like FTlD, AlS is a neurodegenerative 
disorder in which loss of motor neurons leads to progres-
sive weakness of the voluntary muscles. FTlD and AlS 
show important genetic overlap with mutations identified in 
the same genes, e.g., the common g4C2 repeat expansion in 
the chromosome 9 open reading frame 72 gene (C9orf72) 
and less frequently, mutations in the valosin containing 
protein (VCP), fused in sarcoma (FUS), TAr DNA-binding 
protein (TARDBP) and ubiquilin 2 (UBQLN2) genes [5, 8, 
30, 31, 37].
Sequencing of the gene coding for sequestosome 1 
(SQSTM1) in AlS patients identified several rare mutations 
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[7]. Some of these mutations had been associated with 
Paget disease of bone (PDB [9, 14, 16]), a localized chronic 
bone disorder characterized by abnormalities of bone archi-
tecture and marrow fibrosis, resulting in an osteodystrophia 
deformans. Of interest, FTlD, PDB and inclusion body 
myopathy (IBM) had previously been genetically linked 
by mutations in VCP [13, 36, 38]. recently, rare mutations 
in SQSTM1 were also reported in FTlD patients [17, 28]. 
The observation of rare mutations (1–3 %) in both FTlD 
and AlS patients suggested an involvement of the protein 
SQSTM1, also known as p62, in these pathologies possibly 
through a common disease pathomechanism. The p62 pro-
tein is a stress-responsive ubiquitin-binding protein shown 
to have a role in degradation of polyubiquitinated pro-
teins via the proteasome pathway or autophagic processes 
[26]. It is present in neuronal and glial ubiquitin-positive 
inclusions in different tauopathies and synucleinopathies, 
including Alzheimer disease, FTlD, dementia with lewy 
bodies, Parkinson disease, Huntington disease and multiple 
system atrophy [15, 20, 23]. Also in FTlD, with or without 
AlS, p62 co-localizes with TDP-43 and FUS in brain and/
or spinal cord [2, 6, 32]. recently, p62 positive but TDP-43 
negative immunoreactivity, extending to the pyramidal cell 
layer of the hippocampus, basal ganglia and cerebellum, 
has been recognized as a distinctive feature of C9orf72-
associated FTlD and AlS [1, 34]. Aggregating dipeptide 
repeats (DPrs), translated from the expanded ggggCC 
repeat, were identified as the main component of these 
inclusions [21, 22]. In the present study, we aimed at deter-
mining the genetic contribution of mutations in SQSTM1 to 
the etiology of FTlD. Hereto, we analyzed a large study 
population of 1,808 FTlD patients and compared mutation 
data to a set of 3,899 european control individuals, as well 
as 395 european AlS patients.
Materials and methods
The patient and control cohorts under investigation were 
ascertained through the european early-Onset Demen-
tia (eU eOD) consortium (Supplementary table 1) [35]. 
For the present study, DNA and medical/demographic 
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information on 1,808 FTlD patients, originating from 
Belgium, Italy, germany, Spain, Portugal, Sweden, Czech 
republic, Bulgaria and Austria, was contributed by mem-
bers of the consortium. From this patient cohort, 1,706 
patients were clinically diagnosed with FTlD and 102 
with concomitant FTlD and AlS (FTlD-AlS) (for the 
remainder of the manuscript, the FTlD group will refer to 
the 1,706 FTlD patients plus the 102 FTlD-AlS patients). 
The research question of this study was whether genetic 
variations in SQSTM1 affect FTlD risk. Yet, because of 
the close relationship with FTlD, the contributed patient 
cohorts also included a number of AlS patients (n = 395). 
Patients were evaluated and diagnosed with FTlD accord-
ing to the lund and Manchester group criteria [25] and 
for AlS according to the revised el escorial criteria [3]. 
Clinical diagnoses of behavioral variant frontotemporal 
dementia (bvFTD) were based on the international con-
sensus criteria by rascovsky et al. [27] and of progressive 
supranuclear palsy (PSP) on the National Institute of Neu-
rological Disorders and the Society for PSP criteria [18]. 
Neuropathological examination was performed in 105 
autopsied patients, including 67 with FTlD-TDP, 2 FTlD-
UPS, 3 FTlD-tau, 1 FTlD-ni, 4 FTlD unspecified, 21 
AlS-TDP and 7 AlS unspecified. genetic mutation profil-
ing of FTlD- and AlS-associated genes was performed for 
C9orf72 (n = 2,055), grN (n = 1,024), MAPT (n = 854), 
VCP (n = 159), CHMP2B (n = 153), TArDBP (n = 272) 
and FUS (n = 184) and revealed 150 C9orf72 repeat expan-
sion mutations, 24 grN, 5 MAPT, 2 VCP, 1 CHMP2B, and 
2 FUS mutations. A positive family history was defined for 
index patients with first- or second-degree relatives with 
symptoms of dementia or MND. Patients were classified 
as sporadic when no other affected family members were 
reported. Patients from whom no information on family 
history could be obtained were classified as ‘family his-
tory undocumented’. As control group, we sequenced 1,625 
age- and origin-matched Western-european individuals 
with no personal or family history of neurodegenerative 
or psychiatric diseases and a Mini Mental State examina-
tion (MMSe) score >26. We further analyzed whole-exome 
sequencing (WeS) data of 2,274 german non-demented 
individuals [10, 40]. Together, 3,899 control persons were 
investigated for coding variants in SQSTM1.
For all participants, informed consent for participation 
in the genetic studies was obtained according to sampling 
protocols that were approved by the ethics Committee of 
the respective hospitals. The protocols for the genetic stud-
ies were approved by the ethics Committee of the Univer-
sity of Antwerp, Belgium.
Sample quality control
30 µl at 20 ng/µl of genomic DNA (gDNA) was requested, 
and concentration and purity were checked spectrophoto-
metrically using the Trinean DropSense96 UV/VIS drop-
let reader for all consortium samples. gender and DNA 
fingerprint were determined for all DNA samples using an 
in-house developed multiplex polymerase-chain reaction 
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(PCr) genomic DNA Fingerprint panel comprising 13 
short tandem repeat (STr) markers distributed over mul-
tiple autosomal loci—D20S480, D22S1174, D3S1287, 
D3S1744, D3S1764, D7S672, D7S2426, D8S1746, 
D14S1005, D20S866, D10S1237, D20S912, D6S965—
and two sex chromosome markers—DXS1187, chrom Y: 
2655362–2655672—to enable fast and accurate sample 
identification and gender determination in a single PCr. 
Fig. 1  SQSTM1 mutations identified in FTlD and AlS patient 
cohorts ascertained with the european eOD consortium. a Sequence 
alignment for patient-specific mutations showing evolutionary con-
servation across species. b In the blue panel, SQSTM1 mutations 
identified in the present study in patients (top) and control individu-
als (bottom) are presented on the primary structure if the p62 protein 
indicating known functional domains. Mutations absent from tested 
and published controls are in red. Mutations not previously associated 
with FTlD, AlS, or PDB are in red and bold. In the green panel, 
SQSTM1 mutations reported in previous studies are given [7, 11, 17, 
28, 29, 33]. Mutations absent from tested and published controls are 
in green. Functional domains according to [11]: PB1 = Phox and 
Bem1p domain; ZZ = zinc finger motif; TrAF6 = TNF receptor–
associated factor 6; lIr = lC3 interaction region; PeST1 = pro-
line (P), glutamic acid (e), serine (S), and threonine (T) domain 1; 
PeST2 = PeST domain 2; UBA = ubiquitin-associated domain
402 Acta Neuropathol (2014) 128:397–410
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After selective amplification of 20 ng gDNA under empiri-
cally defined reaction conditions, amplification products 
were size separated on an ABI 3730 automatic sequencer 
(Applied Biosystems) using geneScan-600 lIZ (Applied 
Biosystems) as internal size standard and genotypes were 
assigned using in-house developed TracI genotyping soft-
ware (http://www.vibgeneticservicefacility.be). Duplicate 
samples, gender mismatches and failed samples due to low 
Table 1  SQSTM1 mutations present only in patients and associated clinical phenotypes
Functional domains according to [11] (Fig. 1b)
bvFTD behavioral variant frontotemporal dementia, MND motor neuron disease, PSP progressive supranuclear palsy, PNFA progressive non-
fluent aphasia, F familial, S sporadic, U family history undocumented
a
 Indicates variants not previously associated with AlS, FTlD or PDB [7, 11, 17, 28, 29, 33]. For a complete description of SQSTM1 muta-
tions, see Supplementary table 2
b
 Clinical subdiagnosis is given where documented
c
 After revision of the medical records of the mutation carriers, a diagnosis of possible PDB was made in hindsight in this patient
Mutation Functional 
domain




Age at onset 
(years)
Age at death 
(years)
FTlD
 p.Ala16Vala Italian M FTlD-AlS U 71 74
 p.Asp80glua PB1 Italian F FTlD bvFTD F 71 85
 p.Val90Met PB1 Portuguese F FTlD bvFTD U 41
 p.Arg212Cysa Austrian M FTlD-AlS F 63 66
 p.gly219Vala Portuguese M FTlD bvFTD F 52
 p.Ser226Proa TrAF6 Spanish M FTlD bvFTD S 61
 p.Pro228leu TrAF6 german M FTlD bvFTD S 57
 p.Pro232Thra TrAF6 Portuguese F FTlDc bvFTD F 55 68
 p.glu280dela PeST1 Italian F FTlD PSP F 73
 p.Arg321His lIr Italian F FTlD U 68
 p.Asp329glya lIr Spanish M FTlD bvFTD U 78 84
 p.Pro348leu PeST2 Italian M FTlD PNFA F 74
 p.Pro387leu UBA Italian F FTlD PNFA F 65
 p.Pro387leu UBA Italian M FTlD bvFTD S 66
 p.(glu396*) UBA Czech M FTlD bvFTD S 43 47
 p.Thr430Proa UBA Portuguese M FTlD bvFTD S 58 63
AlS
 p.Arg107Trpa Spanish F AlS MND S 58 62
 p.Asp129Asna ZZ Flemish M AlS S 62
 p.Asp258Asna german F AlS F 52 62
Table 2  SQSTM1 mutations 
present in patients and control 
individuals
Functional domains according 
to [11] (Fig. 1b)
a
 Indicates variants not 
previously associated with 
AlS, FTlD or PDB [7, 11, 
17, 28, 29, 33]. For a complete 
description of the SQSTM1 
mutations, see Supplementary 
table 2
Mutation Functional domain FTlD n = 1,808 AlS n = 395 Controls n = 3,899
p.Ala17Vala 1 1
p.Ala33Val PB1 1 1
p.lys103Arg PB1 1 2
p.Ala117Val 1 3
p.Pro118Ser 1 2
p.Val153Ile ZZ 1 3
p.lys238glu TrAF6 17 6 14
p.glu274Asp PeST1 109 22 79
p.Arg321Cys lIr 3 1 1
p.Pro392leu UBA 15 3 11
p.Pro439leu UBA 2 2
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DNA quality or contamination were excluded, resulting in 
the final study population of 1,808 FTlD, 395 AlS, and 
1,625 control individuals.
SQSTM1 sequencing
For the 1,808 FTlD, 395 AlS and 1,625 control indi-
viduals, the 8 coding exons and intron–exon boundaries 
were amplified by PCr of gDNA, followed by Sanger 
sequencing (NM_003900.4, primers available on request). 
Sequences were analyzed using the software package 
NovoSNP [39] and confirmed by visual inspection of the 
DNA sequence traces. Available WeS data on an additional 
2,274 german controls were checked for SQSTM1 coding 
variants [10, 40].
genetic variations were further verified in the Database 
of Single-Nucleotide Polymorphisms (dbSNP Build ID 137; 
Url http://www.ncbi.nlm.nih.gov/SNP/); the exome variant 
server (eVS) of the National Heart, lung, and Blood Insti-
tute gO exome Sequencing Project (Seattle, WA, USA; 
Url http://evs.gs.washington.edu/eVS/), and the 1,000 
genomes project (Url http://www.1000genomes.org/). The 
effects of rare coding variations in SQSTM1 on protein struc-
ture and function were predicted using PMUT (http://mmb2.
pcb.ub.es:8080/PMut/), SNPs&go (http://snps.uib.es/snps-
and-go//snps-and-go.html) and Provean/SIFT (http://
sift.jcvi.org/www/SIFT_enst_submit.html).
Statistical analysis
We determined rare variants as genetic variants with an 
MAF <0.01 and performed a rare variant burden analysis 
following a stepwise approach. Alleles of all rare variants 
were first collapsed across the entire protein. Subsequently, 
calculations were repeated for rare variants associated with 
functional domains only. SQSTM1 functional domains 
were determined according to [11] (Fig. 1b). Finally, rare 
variant data were calculated for each of the seven protein 
domains independently.
Calculations were performed in our source dataset and 
in a meta-analysis considering all published datasets gener-
ated by full exonic sequencing of SQSTM1 in both FTlD 
patient and control groups [7, 17, 28] combined with the 
present study. Overall allele frequencies between patients 
and control individuals were compared using χ2 statistics. 
In the per domain analyses p values were corrected for 
seven tests, corresponding to the seven functional domains. 
rare variant association analysis was limited to the FTlD 
cohort due to the insufficient power of the AlS cohort to 
obtain significant association.
Neuropathology of SQSTM1
Formalin fixed, paraffin-embedded tissue blocks from 
neocortical areas, basal ganglia, thalamus, hippocampus, 
Table 3  Descriptives of the SQSTM1 variants found in control individuals only
On cDNA level exon On protein level Functional domain dbSNP
NM_003900.4:c.286C>T exon 2 NP_003891.1:p.(Arg96*) PB1
NM_003900.4:c.308A>g exon 3 NP_003891.1:p.Arg107gln
NM_003900.4:c.322g>T exon 3 NP_003891.1:p.Asp108Tyr
NM_003900.4:c.329g>A exon 3 NP_003891.1:p.Arg110His
NM_003900.4:c.355C>g exon 3 NP_003891.1:p.Arg119gly
NM_003900.4:c.374A>g exon 3 NP_003891.1:p.Asn125Ser
NM_003900.4:c.415C>T exon 3 NP_003891.1:p.Arg139Cys ZZ
NM_003900.4:c.539C>T exon 4 NP_003891.1:p.Ser180leu
NM_003900.4:c.650g>A exon 4 NP_003891.1:p.Arg217His
NM_003900.4:c.711_713delgAA exon 5 NP_003891.1:p.lys238del TrAF6
NM_003900.4:c.795_796delinsTT exon 6 NP_003891.1:p.[Arg265Ser(;) Ser266Arg] PeST1
NM_003900.4:c.833C>T exon 6 NP_003891.1:p.Thr278Ile PeST1 rs200445838
NM_003900.4:c.923C>T exon 6 NP_003891.1:p.Ala308Val
NM_003900.4:c.955g>A exon 6 NP_003891.1:p.glu319lys rs61748794
NM_003900.4:c.965_966delCT exon 6 NP_003891.1:p.Pro322 fs lIr
NM_003900.4:c.1001_1003delgAg exon 7 NP_003891.1:p.gly334del lIr
NM_003900.4:c.1045T>A exon 7 NP_003891.1:p.Ser349Thr PeST2
NM_003900.4:c.1084g>A exon 7 NP_003891.1:p.glu362lys
NM_003900.4:c.1108T>C exon 7 NP_003891.1:p.Ser370Pro rs143956614
NM_003900.4:c.1273g>A exon 8 NP_003891.1:p.gly425Arg UBA
NM_003900.4:c.1277C>T exon 8 NP_003891.1:p.Ala426Val UBA
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brainstem and cerebellum were evaluated. In addition to 
Hematoxylin and eosin staining, the following mono-
clonal (mouse) antibodies were used for immunohisto-
chemistry: monoclonal anti-p62 (1:1,000, BD Transduc-
tion, lexington KY, USA), anti-tau AT8 (pS202/pT205, 
1:200, Pierce Biotechnology, rockford, Il, USA), 
anti-phospho-TDP-43 (pS409/410, 1:2,000, Cosmo Bio, 
Tokyo, Japan), anti-α-synuclein (1:2,000, clone 5g4, 
roboscreen, leipzig, germany; specific for disease-
associated form), anti-Aβ (1:50, clone 6F/3D, Dako, 
glostrup, Denmark). The DAKO enVision© detection 
kit, peroxidase/DAB, rabbit/mouse (Dako, glostrup, 
Fig. 2  Neuropathology observed in SQSTM1 mutation carriers. 
Immunostaining for phospho-TDP-43 in the temporal cortex (a, b) 
and in the granule cells of the dentate gyrus (c, d) in a patient with 
a SQSTM1 p.(glu396*) mutation (a, c) and a second patient with a 
SQSTM1 p.Arg212Cys—C9orf72 double mutation (b, d). Notably, 
p62 immunoreactivity is less in the dentate gyrus (e, f) and lacking in 
the cerebellar granule cell layer (g, h) in the p.(glu396*) case (e, g) 
as compared to the p.Arg212Cys patient with the additional C9orf72 
repeat expansion mutation (f, h). Scale bar represents 25 µm for all
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Denmark) was used for visualization of the antibody 
reactions.
Results
Information on family history was available for 76.2 % 
(1,378/1,808) of the FTlD patients and 83.0 % (328/395) 
of AlS patients (Supplementary table 1). In the FTlD 
group, 35.2 % (636/1,808) had a positive family his-
tory while 41.2 % (744/1,808) were considered sporadic 
patients. In the AlS group, 14.9 % (59/395) had a family 
history of disease while 68.1 % (269/395) were sporadic 
patients. Onset age distribution was 63 ± 9.9 years in the 
FTlD group and 58 ± 13.7 years in the AlS group com-
pared to an age at inclusion of 66 ± 12.4 years in the con-
trol group (Supplementary table 1).
Mutation screen of SQSTM1 in FTlD
In total we identified 25 rare, heterozygous variations 
that affected the coding region of SQSTM1, including 23 
missense mutations, 1 nonsense mutation and one small 
in-frame deletion (Tables 1, 2, Supplementary table 2; 
Fig. 1). Fifteen mutations were present in 16 patients and 
were absent from 3,899 control individuals (Table 1). 
The majority of the 15 mutations involved highly con-
served amino acid residues in SQSTM1 and were pre-
dicted to be pathogenic (Fig. 1a, Supplementary table 3). 
Among the 16 mutation carriers, 7 had a positive family 
history of disease and 2 patients had concomitant AlS 
(Table 1). Nine patients carried a novel mutation not pre-
viously associated with FTlD, AlS or PDB (p.Ala16Val, 
p.Asp80glu, p.Arg212Cys, p.gly219Val, p.Ser226Pro, 
p.Pro232Thr, p.glu280del, p.Asp329gly and p.Thr430Pro) 
(Fig. 1b). The remaining six mutations had been reported 
in AlS (p.Val90Met, p.Pro228leu and p.Pro348leu) [7, 
28, 29], FTlD (p.Arg321His, p.Pro387leu) [17] or PDB 
(p.Pro387leu, p.(glu396*)) [28] (Fig. 1b). except for 
p.Ala16Val, p.Arg212Cys and p.gly219Val, all other muta-
tions were located in a predicted functional protein domain 
of SQSTM1/p62 (Fig. 1b). In addition to the patient-only 
mutations, we identified another 10 missense mutations 
(p.Ala17Val, p.Ala33Val, p.lys103Arg, p.Ala117Val, 
p.Pro118Ser, p.lys238glu, p.glu274Asp, p.Arg321Cys, 
p.Pro392leu, p.Pro439leu) that were also present in con-
trol individuals at low frequency (Table 2). except for 
p.glu274Asp (MAF of 0.024), all were present in less than 
1 % of control individuals. p.Ala17Val was a novel vari-
ation not previously reported in FTlD, AlS and/or PDB 
patients. We identified another 21 variants present in con-
trol individuals only (Table 3). When considering all rare 
Table 4  SQSTM1 mutations published in previous studies
Mutations published in previous studies [7, 11, 17, 28, 29, 33] absent from published control persons or control persons tested in the present 
study are listed
a
 This mutation was compound heterozygous with p.Val153Ile in one Japanese AlS patient [29], p.Val153Ile was also observed in 3 control 
individuals of the present study. Fecto et al. [7] tested 546 AlS and 724 controls. rubino et al. [28] tested 170 FTlD, 124 AlS, and 145 con-
trols. Teyssou et al. [33] tested 164 AlS and 360 controls. Hirano et al. [11] tested 61 AlS and 500 controls. le Ber et al. [17] tested 188 FTlD, 
164 AlS, and 352 controls. Shimizu et al. [29] tested 1 AlS and 189 controls
Mutation Functional domain FTlD AlS Origin Study
p.Ala53Thr PB1 1 Japanese Hirano et al. [11]
p.Met87Val PB1 1 French Teyssou et al. [33]
p.Val90Meta PB1 1 Japanese Shimizu et al. [29]
p.lys102glu PB1 1 French Teyssou et al. [33]
p.Arg110Cys 2 1 French le Ber et al. [17]
p.Pro228leu TrAF6 1 euro-American Fecto et al. [7]
p.lys238del TrAF6 1 euro-American Fecto et al. [7]
p.Val259leu 1 Italian rubino et al. [28]
p.Ser318Pro 1 euro-American Fecto et al. [7]
p.Arg321His lIr 2 1 French le Ber et al. [17]
p.lys344glu lIr 1 Italian rubino et al. [28]
p.Pro348leu PeST2 1 Italian rubino et al. [28]
p.Ala381Val 1 1 French le Ber et al. [17]
p.Pro387leu UBA 1 French le Ber et al. [17]
p.g351_P388del UBA 1 French Teyssou et al. [33]
p.gly411Ser UBA 1 euro-American Fecto et al. [7]
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variants (MAF <0.01) observed in FTlD patients an over-
all frequency was calculated of 3.2 % (58/1,808).
Mutation screen of SQSTM1 in AlS
For comparison with our FTlD findings, we analyzed 
the 395 AlS patients that were concurrently ascertained 
within the eU eOD consortium (Fig. 1). We identified 
three novel missense mutations present only in the AlS 
patients (p.Arg107Trp, p.Asp129Asn and p.Asp258Asn) 
(Table 1) and five other missense mutations (p.Val153Ile, 
p.lys238glu, p.glu274Asp, p.Arg321Cys and 
p.Pro392leu) also present in control individuals at low fre-
quency (Table 2, Supplementary table 2).
Association of rare SQSTM1 variants
We performed a burden analysis collapsing all rare vari-
ants with an MAF <0.01 across the whole protein. The 
same frequency of rare alleles was calculated for FTlD 
patients 0.016 (58/3,616 rare variant alleles) as for control 
individuals 0.016 (125/7,798; p value = 0.997, n.s.). We 
repeated the same analysis for rare variants present in func-
tional domains only, resulting in a shift in allele frequen-
cies of 0.014 (52/3,616) in FTlD versus 0.011 (84/7,798) 
controls, although not reaching statistical significance 
(p = 0.098). To increase genetic power, we considered 
all published datasets that were generated by full exonic 
sequencing of SQSTM1 in both FTlD patient and control 
groups [7, 17, 28] and included the data in a meta-analysis 
with the present study comprising mutant allele frequencies 
in 4,332 FTlD and 10,240 control alleles. Burden analy-
sis of all rare variants across the protein showed again no 
increase in patients (70/4,332 = 0.016 in FTlD versus 
142/10,240 = 0.014 in controls; p value = 0.291, n.s.), but 
for the rare variants associated with functional domains a 
marked significant increase could be calculated of 0.014 
(61/4,332 rare variant alleles) in FTlD patients versus 
0.009 (97/10,240) in control individuals (relative risk over-
all (rr) = 1.49 [95 % CI 1.08–2.06]; p value = 0.014).
Subsequently, we investigated which of the functional 
domains were most contributing to the association. rare 
variant data were calculated for each of the seven protein 
domains. In our source, FTlD cohort significant associa-
tion was found with the C-terminal ubiquitin-associated 
(UBA) domain in patients (21/3,616 = 0.006 rare vari-
ant alleles) versus control individuals (20/7,798 = 0.003) 
(rr = 2.27 [95 % CI 1.23–4.20]; p value = 0.007, cor-
rected p value = 0.049). In the meta-dataset, statistically 
significant clustering in the UBA domain was confirmed 
in FTlD (23/4,332 = 0.005 rare variant alleles) ver-
sus control individuals (25/10,240 = 0.002) (rr = 2.18 
[95 % CI 1.24–3.85]; p value = 0.006, corrected p 
value = 0.042). In addition, also the lC3 interaction region 
(lIr) domain showed suggestive clustering of rare vari-
ants in FTlD (8/4,332 = 0.002) versus control individuals 
(5/10,240 = 0.0005) (rr = 3.79 [95 % CI 1.24–11.58]; p 
value = 0.012, corrected p value = 0.084).
Histopathology associated with SQSTM1 mutations
Detailed histopathology was performed on autopsy brain 
of two carriers of a nonsense mutation p.(glu396*) located 
in the UBA domain and a missense mutation p.Arg212Cys 
in a patient who also carried a C9orf72 repeat expansion. 
Both cases showed widespread phospho-TDP-43 immu-
noreactive inclusions in neurons and glial cells. In the 
p.(glu396*) carrier, frontal and temporal cortical areas 
mainly displayed neuronal cytoplasmic inclusions. Neu-
ronal cytoplasmic inclusions were further abundant in the 
granule cells of the dentate gyrus. In addition, many glial 
phospho-TDP-43 inclusions were seen in the white matter. 
Although this brain suffered severe ischemic/hypoxic dam-
age, inclusion bodies were clearly recognized as a distinc-
tive feature. In contrast, neuropathological features of the 
p.Arg212Cys carrier revealed alterations reminiscent of the 
C9orf72 pathology, including the characteristic p62-pos-
itive but phospho-TDP-43-negative inclusions in the hip-
pocampal pyramidal layer and cerebellar granule cells 
(Fig. 2).
Discussion
Previous studies in AlS (total n = 895) [7, 11, 28, 33], 
and FTlD (total n = 358) [17, 28] estimated the frequency 
of SQSTM1 coding mutations at 2.42–3.28 % in AlS 
and 1.76–2.13 % in FTlD. Because of this relatively low 
prevalence, large patient and control groups are needed to 
obtain a reliable estimation of the mutation frequency of 
SQSTM1. Mutations in SQSTM1 were first described in 
patients with PDB [16]. Up to one-third of patients with 
familial PDB are explained by a SQSTM1 mutation, with 
p.Pro392leu as the most commonly observed mutation 
[4]. A relationship between PDB and FTlD has been pre-
viously demonstrated by the identification of causal muta-
tions in VCP in families segregating the rare syndrome of 
inclusion body myopathy with Paget disease of bone and 
frontotemporal lobar degeneration (IBMPFD) [38]. later 
studies demonstrated that VCP mutations express signifi-
cant clinical heterogeneity and patients can present with 
all, a combination of two or just one of the three core phe-
notypes of IBMPFD [24, 36]. Also more recently, WeS 
identified a VCP mutation segregating in a family with 
AlS and subsequent screenings in AlS patients identified 
additional VCP mutations [12].
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In this study, we analyzed a european cohort of 1,808 
FTlD patients for mutations in SQSTM1 and identified 
25 mutations in the coding sequence of which 15 muta-
tions in 16 patients were absent from 3,899 control per-
sons. This resulted in a mutation frequency for SQSTM1 
of 0.9 % overall and 1.1 % in familial FTlD patients. 
Some of the mutations are listed in dbSNP Short genetic 
Variations database, the 1,000 genomes Project database 
or the exome variant server (eVS), yet at very low fre-
quencies of MAF ≤0.001 (Supplementary table 2). The 
SQSTM1 mutation frequency that we calculated in FTlD 
is lower than in previous studies. This can potentially be 
explained by the fact that we excluded some of the pre-
viously reported patient-only mutations from our calcu-
lations since they were present in our extended control 
group, though at low frequencies <0.01 % (Fig. 1b). This 
was the case for p.Arg321Cys, p.Ser370Pro, p.gly425Arg 
[7]; p.Ala33Val, p.Pro392leu [7, 17]; p.lys238glu, 
p.glu319lys [28]; p.Pro439leu [11]; and p.Val153Ile 
[7, 29]. In Table 4, all SQSTM1 mutations are listed that 
have been published [7, 11, 17, 28, 29, 33] and were 
absent from published and tested control persons. When 
we considered all rare variants (MAF < 0.01), indifferent 
of whether or not they appeared in control individuals, we 
obtained a mutation frequency of 3.2 % in FTlD patients 
which is the same as calculated in the pooled data analy-
sis of the present and published FTlD cohorts [17, 28]. 
Overall, no statistical association in patients versus control 
individuals was observed when pooling all rare SQSTM1 
variants, not in our study nor in the meta-analysis with 
all published patient and control datasets [7, 17, 28]. Yet, 
when considering only domain-associated variants, a trend 
toward association was observed in our study and a sig-
nificant increase in patients was reached in the more pow-
erful meta-analysis dataset. Per domain analysis indicated 
that association was driven by the UBA domain and pos-
sibly also the lIr domain. The C-terminal UBA domain, 
which is primarily affected in PDB, contained significant 
more variants in FTlD patients when compared to control 
individuals in both our study and the meta-analysis (0.5 
versus 0.2 %) (rrmeta = 2.18 [95 % CI 1.24–3.85]; nomi-
nal p valuemeta = 0.006; corrected p valuemeta = 0.042). 
In the lIr domain through which SQSTM1 binds the 
autophagy effector protein lC3, 0.2 % of FTlD patients 
carried a mutation versus 0.05 % of control individuals 
(rrmeta = 3.79 [95 % CI 1.24–11.58]; nominal p valuem-
eta = 0.012; corrected p valuemeta = 0.084). In contrast to 
rubino and colleagues who sequenced up to 1,700 bp into 
the SQSTM1 promoter and detected 4 variants in 4 out of 
170 FTlD patients absent from 145 control individuals (c. 
−1,221 g>A, c. −1,165 C>T, c. −1,153 C>g, c. −673 
T>C) [28], we did not investigate the SQSTM1 promoter 
for rare variants.
The pathogenicity of SQSTM1 mutations, even those 
that were absent from control individuals, remains unclear 
at this stage. Most of the patient-only mutations involved 
highly conserved amino acid residues, with 75 % of the 
mutations residing in predicted functional domains. In silico 
prediction programs of amino acid changes indicated that 
all mutations might be pathogenic by one or more of the in 
silico programs. Also, the three mutations that resided out-
side predicted domains were scored as deleterious by one to 
all four in silico programs. Of course, these in silico predic-
tions are merely indicative and should be interpreted with 
caution. In contrast to PDB-associated mutations which 
cluster at the UBA domain [11, 16], FTlD mutations are 
mostly distributed throughout the protein as also previously 
reported for AlS, though significantly more mutations seem 
to be located in the UBA domain. Further, le Ber and col-
leagues provided evidence for co-segregation with FTlD 
for two mutations in the UBA domain, p.Pro387leu and 
p.Pro392leu [17]. The p.Pro387leu mutation was also pre-
sent in two unrelated Italian FTlD patients in our study who 
did not share a common haplotype, suggesting a recurrent 
de novo mutation. No DNA of relatives of these two muta-
tion carriers was available to test for co-segregation. Three 
mutation carriers (p.Ala16Val, p.Arg212Cys, p.gly219Val) 
also carried a pathogenic C9orf72 repeat expansion. At this 
stage, we have no clear indication that the co-existence of 
these mutations influences clinical expression of disease. 
Onset ages were not different from those in patients carry-
ing only a SQSTM1 mutation. In a Japanese sporadic late-
onset AlS patient with pathology confirmed predominant 
lower motor neuron disease, a compound heterozygous 
SQSTM1 mutation was detected, p.[Val90Met(;)Val153Ile] 
[29]. We did not observe compound heterozygous SQSTM1 
mutation carriers, though both mutations present in the Jap-
anese patient were also observed in our study, p.Val90Met 
in one FTlD patient and p.Val153Ile in one other FTlD 
patient and three control individuals. One could hypothesize 
that the rare SQSTM1 variants act as high to intermediate 
penetrant risk alleles and in case of the Japanese patient 
both had to be present to exert the clinical profile of AlS.
The hallmark lesions of FTlD-TDP are neuronal and 
glial inclusions with positive immunoreactivity for phospho-
TDP-43. In addition to sporadic patients, until now mutations 
in VCP, GRN and C9orf72 have been associated consistently 
with TDP-43 pathology, while TArDBP mutations are less 
frequently observed in FTlD [19]. Here, we provide histo-
pathological evidence that SQSTM1 mutations are associ-
ated with TDP-43 pathological inclusions. Interestingly, the 
patient with only a SQSTM1 mutation (p.glu396*) showed 
widespread neuronal and glial phospho-TDP-43 pathol-
ogy. The patient (p.Arg212Cys) who carried also a C9orf72 
mutation showed C9orf72-related pathology without other 
noticeable distinctive features. Potential explanations could 
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be that the C9orf72 mutation masked the effect of the SQST-
M1mutation, or that the C9orf72 pathology dominates the 
SQSTM1 pathology. Also the SQSTM1 p.Arg212Cys muta-
tion may well have a lower penetrance and be associated 
with more subtle pathological changes than the (p.glu396*) 
mutation located in the UBA domain. These questions merit 
further investigation and more SQSTM1-positive patholo-
gies will need to be evaluated to resolve these issues. Since 
mutations in SQSTM1 were first linked to PDB, we carefully 
reexamined medical records of all carriers of patient-only 
SQSTM1 mutations for indications of (sub) clinical symp-
toms of PDB. Only in one Portuguese patient carrying the 
p.Pro232Thr mutation located in the TrAF6 domain, the 
diagnosis of possible PDB could be made at hindsight. We, 
however, cannot exclude that the presence of PDB might 
have been missed in the other patients since PDB often 
remains asymptomatic and a diagnosis requires radiography. 
likewise we cannot exclude that some of the control indi-
viduals, who were selected based on absence of dementia-
related symptoms, may have been at risk for/or suffered from 
PDB, in particular, those with the PDB-associated SQSTM1 
p.P392l mutation.
In conclusion, our study represents one of the larg-
est screening efforts of FTlD patients for mutations in 
SQSTM1. Further, we combined the data from our screen-
ing with that of published datasets in a meta-analysis of rare 
SQSTM1 variants in a total of 4,432 FTlD and 10,240 con-
trol alleles. Both our study and the meta-analysis calculated 
a mutation frequency of 3.2 % in FTlD patients. Also, the 
meta-analysis suggested that rare mutations clustering in 
the UBA domain of SQSTM1 may influence disease sus-
ceptibility by doubling the risk for FTlD. Histopathology 
of autopsied brain of SQSTM1 mutation carriers demon-
strated a widespread neuronal and glial phospho-TDP-43 
pathology. Taken together, our findings provide additional 
evidence that SQSTM1 is implicated in the pathogenicity of 
FTlD/AlS spectrum diseases.
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